Trends in clinical development timeframes for antiviral drugs launched in the UK, 1981–2014: a retrospective observational study

Abstract

ObjectivesRecent decades have witnessed the development of highly innovative new antiviral drug therapies. However, there are concerns that rising costs and lengthening development times could have implications for future patient access to innovative new drugs. We sought to establish whether the time taken for the clinical development of new antiviral drugs launched in the UK had increased since the 1980s.Design and settingRetrospective observational study of all new antiviral drugs licensed for use in the UK.Primary and secondary outcome measuresDuration of clinical development (from initiation of studies in humans to receipt of Marketing Authorisation), subdivided into clinical trial and regulatory approval periods by the date of Marketing Authorisation Application.Results48 new antiviral drugs were licensed for use in the UK between 1981 and 2014 (inclusive), over half (54%) initially for HIV infection. The overall mean duration of clinical development was 77.2 months, of which 64.6 months was spent in clinical trials before regulatory submission. The total time in clinical development increased from 41.7 months for drugs licensed 1981–1992 to 91.7 months for drugs licensed 2004–2014. This increase was accounted for by an increase in the clinical trials period and not the regulatory approval period, for which there was no observable trend. Drugs initially licensed to treat hepatitis C had a longer duration of clinical development than those indicated for other viral infections. However, the, initially shorter clinical development durations of drugs indicated for HIV infection increased more rapidly across the study period than those indicated for other viral infections.ConclusionsThe time spent by antiviral drugs in clinical development has increased markedly in recent decades despite many initiatives to speed access to innovative new drugs. However, this represents only one part of the translational research pathway, and a complete picture of development timeframes is lacking.

Identification of broad anti-coronavirus chemical agents for repurposing against SARS-CoV-2 and variants of concern

“…De novo development of antivirals is a lengthy and costly process and insufficient to resolve the current crisis in short terms ( Ward et al, 2015 ). Our large scale drug repurposing screen identified broadly acting clinically approved small molecular weight compounds.…”

Tackling the emerging threat of antifungal resistance to human health

“…An obvious solution to the allied problems of limited classes of drugs that may be compromised by dual use is to accelerate drug development. However, this is not a solution that can be achieved rapidly as it takes around 5–7 years from first initiation in human trials to approval of a novel anti-infective 94 , 95 and can cost hundreds of millions of dollars. Timescales and costs are much higher if early development costs are accounted for.…”

Endogenous productivity of demand‐induced R&D: evidence from pharmaceuticals

“…In line with this argument, Ward et al. () report a near doubling in clinical development time for new antiviral drugs, and Getz and Campo () document anywhere from a 20%–70% increase in the complexity of clinical trials based on the number of procedures and visits in trial protocols.…”